XML 31 R19.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Collaborative Arrangements and Licensing Agreements (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2018
AstraZeneca [Member] |
Collaborative Arrangements and Licensing Agreements [Abstract] |
Revenue from Collaborative Relationship | During the three and nine months ended September 30, 2018 and 2017, we earned the following revenue from our relationship with AstraZeneca (in millions, except percentage amounts):
| Three Months Ended September 30, |  | Nine Months Ended September 30, |
| 2018 |  | 2017 |  | 2018 |  | 2017 |
R&D revenue |  | $ | 14.2 |  |  | $ | 4.8 |  |  | $ | 86.5 |  |  | $ | 14.8 |
Percentage of total revenue |  |  | 10 | % |  |  | 4 | % |  |  | 21 | % |  |  | 4 | %
Biogen [Member] |
Collaborative Arrangements and Licensing Agreements [Abstract] |
Revenue from Collaborative Relationship | During the three and nine months ended September 30, 2018 and 2017, we earned the following revenue from our relationship with Biogen (in millions, except percentage amounts):
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2018 |  |  | 2017 |  |  | 2018 |  |  | 2017 |
SPINRAZA royalties (commercial revenue) |  | $ | 70.0 |  |  | $ | 32.9 |  |  | $ | 167.7 |  |  | $ | 60.5 |
R&D revenue |  |  | 34.8 |  |  |  | 54.9 |  |  |  | 66.9 |  |  |  | 137.1 |
Total revenue from our relationship with Biogen |  |  | 104.8 |  |  |  | 87.8 |  |  |  | 234.6 |  |  |  | 197.6 |
Percentage of total revenue |  |  | 72 | % |  |  | 74 | % |  |  | 58 | % |  |  | 57 | %
Bayer [Member] |
Collaborative Arrangements and Licensing Agreements [Abstract] |
Revenue from Collaborative Relationship | During the three and nine months ended September 30, 2018 and 2017, we earned the following revenue from our relationship with Bayer (in millions, except percentage amounts):
| Three Months Ended September 30, |  | Nine Months Ended September 30, |
| 2018 |  | 2017 |  | 2018 |  | 2017 |
R&D revenue |  | $ | 1.9 |  |  | $ | 0.4 |  |  | $ | 3.3 |  |  | $ | 66.0 |
Percentage of total revenue |  |  | 1 | % |  |  | 0 | % |  |  | 1 | % |  |  | 19 | %
Janssen Biotech, Inc. [Member] |
Collaborative Arrangements and Licensing Agreements [Abstract] |
Revenue from Collaborative Relationship | During the three and nine months ended September 30, 2018 and 2017, we earned the following revenue from our relationship with Janssen (in millions, except percentage amounts):
| Three Months Ended September 30, |  | Nine Months Ended September 30, |
| 2018 |  | 2017 |  | 2018 |  | 2017 |
R&D revenue |  | $ | 0.9 |  |  | $ | 3.4 |  |  | $ | 6.6 |  |  | $ | 18.1 |
Percentage of total revenue |  |  | 1 | % |  |  | 3 | % |  |  | 2 | % |  |  | 5 | %
Novartis [Member] |
Collaborative Arrangements and Licensing Agreements [Abstract] |
Revenue from Collaborative Relationship | During the three and nine months ended September 30, 2018 and 2017, we earned the following revenue from our relationship with Novartis (in millions, except percentage amounts):
| Three Months Ended September 30, |  | Nine Months Ended September 30, |
| 2018 |  | 2017 |  | 2018 |  | 2017 |
R&D revenue |  | $ | 7.2 |  |  | $ | 9.9 |  |  | $ | 42.7 |  |  | $ | 21.7 |
Percentage of total revenue |  |  | 5 | % |  |  | 8 | % |  |  | 10 | % |  |  | 6 | %
Roche [Member] |
Collaborative Arrangements and Licensing Agreements [Abstract] |
Revenue from Collaborative Relationship | During the three and nine months ended September 30, 2018 and 2017, we earned the following revenue from our relationship with Roche (in millions, except percentage amounts):
| Three Months Ended September 30, |  | Nine Months Ended September 30, |
| 2018 |  | 2017 |  | 2018 |  | 2017 |
R&D revenue |  | $ | 1.8 |  |  | $ | 4.5 |  |  | $ | 5.4 |  |  | $ | 5.9 |
Percentage of total revenue |  |  | 1 | % |  |  | 4 | % |  |  | 1 | % |  |  | 2 | %
GSK [Member] |
Collaborative Arrangements and Licensing Agreements [Abstract] |
Revenue from Collaborative Relationship | During the three and nine months ended September 30, 2018 and 2017, we earned the following revenue from our relationship with GSK (in millions, except percentage amounts):
| Three Months Ended September 30, |  | Nine Months Ended September 30, |
| 2018 |  | 2017 |  | 2018 |  | 2017 |
R&D revenue |  | $ | 0.1 |  |  | $ | 4.6 |  |  | $ | 1.5 |  |  | $ | 14.4 |
Percentage of total revenue |  |  | 0 | % |  |  | 4 | % |  |  | 0 | % |  |  | 4 | %
PTC Therapeutics [Member] |
Collaborative Arrangements and Licensing Agreements [Abstract] |
Revenue from Collaborative Relationship | During the three and nine months ended September 30, 2018 and 2017, we earned the following revenue from our relationship with PTC (in millions, except percentage amounts):
| Three Months Ended September 30, |  | Nine Months Ended September 30, |
| 2018 |  | 2017 |  | 2018 |  | 2017 |
R&D revenue |  | $ | 12.0 |  |  | $ | 0.0 |  |  | $ | 12.0 |  |  | $ | 0.0 |
Percentage of total revenue |  |  | 8 | % |  |  | — |  |  |  | 3 | % |  |  | — |

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | ions_CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems
Namespace Prefix: | ions_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -URI http://asc.fasb.org/extlink&oid=109250915&loc=d3e13537-108611 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=109250915&loc=d3e13531-108611 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 16 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 21 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592 + Details
Name: | us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementsAndLicensingAgreementsBiogenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementsAndLicensingAgreementsBayerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementsAndLicensingAgreementsRocheMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |